Enzolytics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENZC research report →
Price Chart
About the company
Enzolytics Inc. , a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses.
- CEO
- Steven Sharabura
- IPO
- 2009
- Employees
- 1
- HQ
- Plano, TX, US
Get TickerSpark's AI analysis on ENZC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.93M
- P/E
- -14.94
- PEG
- -0.08
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -37.81
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.08%
- ROIC
- 0.07%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-5,522+75.0%
- Op Income
- $-82,983
- Net Income
- $-92,239+76.6%
- EPS
- $0.00+100.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.51
- RSI (14)
- 43
- Avg Volume
- 3.22M
No earnings-call transcripts are available for ENZC yet.
- Free Float
- 98.0%
- Shares Outstanding
- 4.83B
- Float Shares
- 4.74B
Our ENZC coverage
Recent articles, reports, and earnings notes.
No research on ENZC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENZC report →Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
accesswire.com · Sep 18
Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
accesswire.com · Sep 9
Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
accesswire.com · Aug 20
Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
accesswire.com · Jul 31
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
accesswire.com · Jul 29
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
accesswire.com · Jul 26
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
accesswire.com · Jul 1
Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
accesswire.com · Jun 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.